Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

NEW YORK--Bristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the agreement were not disclosed.

The agreement supports Bristol-Myers Squibb's long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

The innate immune system is the body's first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter athttp://twitter.com/bmsnews.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.